Thermo Fisher Scientific: Why Wall Street Says ‘Buy’
Analysts’ recommendations for Thermo Fisher Scientific
Let’s take a look at Wall Street analysts’ recommendations and 12-month target prices for Thermo Fisher Scientific (TMO). As per a Reuters survey comprising 15 brokerage firms, Thermo Fisher Scientific is rated a “buy” by 14 analysts while only one analyst recommended the stock as a “hold.” No analyst provided a “sell” rating on TMO.
Interested in ABT? Don't miss the next report.
Receive e-mail alerts for new research on ABT
As of September 29, the stock’s consensus 12-month target price is $207, representing around an 11% return potential. This target price compares to the stock’s previous-day closing price of $186.5 per share.
From analysts’ most recent recommendations on the stock, we find that the lowest 12-month target price for TMO stands at $140. The highest 12-month target price is $225. These prices represent the highest 12-month return potential of around 21% and a maximum downside return potential of -25% on the stock for investors over 12 months.
On September 26, encouraged by the company’s positive organic growth and high-growth acquisitions, Goldman Sachs assumed coverage on the stock with a rating of “conviction buy.” The company has a target price of $225. On September 10, Cowen and Company reiterated its “outperform” rating on the stock. It has a price target of $220 on TMO. Barclays also reaffirmed its “overweight” rating on TMO on September 25, driven by expected revenue synergies from Thermo Fisher Scientific’s Patheon acquisition.
Abbott Laboratories (ABT), Zimmer Biomet Holdings (ZBH), and Medtronic (MDT) are some of the major competitors for Thermo Fisher Scientific. The average analyst target prices for these stocks are $207, $135.65, and $91.1, respectively. These prices represent returns of 11%, 17.3%, and 17.2%, respectively, over the next 12 months.
To gain diversified exposure to Thermo Fisher Scientific, investors can consider the iShares Core S&P 500 ETF (IVV). IVV invests 0.35% of its total holdings in Thermo Fisher Scientific.